Mystery Drug Clears Parkinson's Proteins in Mice
Why it matters: This discovery could lead to the first disease-modifying treatment for the 10 million people worldwide affected by Parkinson's disease.
- Compound X improved mobility and balance in mice with Parkinson's-like symptoms by enhancing the glymphatic system, which clears toxic alpha-synuclein protein clumps.
- Zhao Yan at Swinburne University of Technology presented findings at the Oxford Glymphatic and Brain Clearance Symposium, highlighting the drug's potential as a disease-modifying treatment.
- Researchers utilized a novel mouse model where misfolded alpha-synuclein was introduced nasally, more accurately replicating human Parkinson's progression than previous models.
- The FDA-approved drug (compound X) was administered to half of the mice, with 80% successfully completing a mobility task, compared to only 10% in the control group.
A mysterious drug, referred to as compound X, has shown significant promise in treating Parkinson's-like symptoms in mice by boosting the brain's natural waste disposal system. Researchers are keeping its identity secret to secure intellectual property, believing it could be the first disease-modifying treatment for the condition.
